Insider Selling: Krystal Biotech (NASDAQ:KRYS) Director Sells 25,000 Shares of Stock

Krystal Biotech, Inc. (NASDAQ:KRYS) Director Dino Rossi sold 25,000 shares of the firm’s stock in a transaction that occurred on Friday, August 14th. The stock was sold at an average price of $329.12, for a total transaction of $8,228,000.00. Following the sale, the director owned 50,000 shares of the company’s stock, valued at $16,456,000. This represents a 33.33% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Krystal Biotech Price Performance

Shares of KRYS stock traded up $3.93 during trading on Friday, hitting $332.27. 167,864 shares of the stock traded hands, compared to its average volume of 345,531. Krystal Biotech, Inc. has a 52-week low of $136.73 and a 52-week high of $382.54. The firm has a market capitalization of $9.84 billion, a P/E ratio of 41.64 and a beta of 0.53. The firm’s fifty day moving average price is $343.76 and its 200-day moving average price is $299.02.

Krystal Biotech (NASDAQ:KRYS) last posted its earnings results on Monday, August 3rd. The company reported $1.79 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.70 by $0.09. Krystal Biotech had a return on equity of 19.34% and a net margin of 54.82%.The company had revenue of $119.22 million during the quarter, compared to analysts’ expectations of $120.93 million. As a group, equities research analysts expect that Krystal Biotech, Inc. will post 7.68 earnings per share for the current year.

Analyst Upgrades and Downgrades

KRYS has been the subject of a number of recent analyst reports. Weiss Ratings raised Krystal Biotech from a “buy (b-)” rating to a “buy (b)” rating in a research report on Monday, August 3rd. Jefferies Financial Group reaffirmed a “buy” rating and issued a $474.00 target price on shares of Krystal Biotech in a research report on Monday, July 13th. Chardan Capital raised shares of Krystal Biotech to a “strong-buy” rating in a research note on Monday, August 3rd. Royal Bank Of Canada started coverage on shares of Krystal Biotech in a research note on Friday. They issued an “outperform” rating and a $400.00 price target on the stock. Finally, Bank of America upped their price objective on shares of Krystal Biotech from $364.00 to $396.00 and gave the stock a “buy” rating in a report on Tuesday, July 14th. One equities research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and two have issued a Hold rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $365.40.

Institutional Investors Weigh In On Krystal Biotech

A number of institutional investors have recently modified their holdings of KRYS. BlackRock Inc. purchased a new stake in shares of Krystal Biotech in the 2nd quarter valued at $1,554,113,000. William Blair Investment Management LLC acquired a new position in Krystal Biotech in the 2nd quarter valued at about $211,909,000. Soleus Capital Management L.P. grew its position in Krystal Biotech by 108.9% in the 2nd quarter. Soleus Capital Management L.P. now owns 922,958 shares of the company’s stock valued at $126,870,000 after acquiring an additional 481,200 shares in the last quarter. Norges Bank purchased a new stake in Krystal Biotech during the fourth quarter worth about $70,159,000. Finally, Janus Henderson Group PLC increased its stake in Krystal Biotech by 2,078.9% during the fourth quarter. Janus Henderson Group PLC now owns 219,440 shares of the company’s stock worth $54,147,000 after purchasing an additional 209,369 shares during the period. 86.29% of the stock is owned by institutional investors and hedge funds.

About Krystal Biotech

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.